NCT00219180

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

An 8-week Multi-center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,797 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	aliskiren

Timeline

• Start date: 2005-06-01
• Primary completion: 2006-09-01
• Completion: 2006-09-01
• First posted: 2005-09-22
• Last updated: 2017-05-17

Locations

2 sites across 2 countries: United States, Germany